Alpha-mangostin suppresses receptor activator nuclear factor-κB ligand-induced osteoclast formation and bone resorption in RAW264.7 cells by inhibiting the extracellular signal-regulated kinase and c-Jun N-terminal kinase signaling

Articles

Abstract
Pharmacognosy Magazine,2018,14,56,390-396.
Published:August 2018
Type:Original Article
Authors:
Author(s) affiliations:

Rong-Hua Hong, Yi-Min Liang, Han-Song Pan, Zhao-Hui Cheng, Yong-Hua Li
Department of Orthopedic Surgery, Huangyan Hospital, Wenzhou Medical University, Huangyan; Department of Orthopedic Surgery, Taizhou First People's Hospital, Huangyan, Taizhou, Zhejiang 318020, China

Abstract:

Background: Excessive osteoclast formation and over-activated function lead to a series of osteoclast-related diseases. Suppression of osteoclastogenesis is likely to be an effective means for the treatment of these diseases. Objective: In this study, we investigated the effects of alpha-mangostin (α-MAG), a natural compound derived from Garcinia mangostana, on osteoclast formation and function in RAW264.7 cells. Materials and Methods: Different concentrations of α-MAG were used to explore its effects on receptor activator of nuclear factor-κB ligand (RANKL)-induced osteoclastogenesis and further, we investigated the mechanism by Western Blotting. Results: The study revealed that α-MAG attenuated RANKL-induced osteoclastogenesis. Moreover, the effects were confirmed to be caused by the suppression of the phosphorylation of the extracellular signal-regulated kinase (ERK) and c-Jun N-terminal kinase (JNK) signaling and this inhibitory effect could be rescued by the administration of the JNK and p38 agonist anisomycin. Conclusion: The study results demonstrated that α-MAG could impair RANKL-induced osteoclastogenesis by inhibiting the ERK and JNK signaling pathways in RAW264.7 cells.

PDF
Keywords